A randomised, double blind, placebo-controlled, phase 2a study of the efficacy, safety and pharmacokinetics of MLN3897 in patients with rheumatoid arthritis taking methotrexate

Submission date 22/01/2007	Recruitment status No longer recruiting	Prospectively re	
		[] Protocol	
Registration date 22/01/2007	Overall study status Completed	Statistical analy	
		[X] Results	
Last Edited	Condition category	[] Individual partic	
15/01/2021	Musculoskeletal Diseases		

- egistered
- ysis plan
- cipant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s) Scientific

Contact name Prof P P Tak

Contact details Academic Medical Center (AMC) Department of Clinical Immunology and Rheumatology P.O. Box 22660 Amsterdam Netherlands 1100 DD +31 (0)20 566 2171 p.p.tak@amc.nl

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers NL842, NTR856

Study information

Scientific Title

A randomised, double blind, placebo-controlled, phase 2a study of the efficacy, safety and pharmacokinetics of MLN3897 in patients with rheumatoid arthritis taking methotrexate

Study objectives MLN3897 is safe and improves signs and symptoms of rheumatoid arthritis.

Ethics approval required Old ethics approval format

Ethics approval(s)

Approval received from the Medical Ethical Committee on the 16th November 2006, amendment one approved on the 29th November 2006 (ref: 06-139).

Study design Randomised, placebo controlled, parallel group, double blinded multicentre trial

Primary study design Interventional

Secondary study design Randomised controlled trial

Study setting(s) Not specified

Study type(s) Treatment

Participant information sheet

Health condition(s) or problem(s) studied Rheumatoid arthritis

Interventions 12 week treatment with MLN3897 or placebo, taken orally once daily.

Intervention Type Drug

Phase Phase II

Drug/device/biological/vaccine name(s)

MLN3897, methotrexate

Primary outcome measure

1. Percentage of ACR20 response at day 84 in MLN3897 versus placebo treated patients

2. Safety assessments

Secondary outcome measures

- 1. Disease Activity Scale (DAS28) response
- 2. ACR50/ACR70 response
- 3. Change in individual components of ACR criteria
- 4. Time to ACR20 response

Overall study start date

01/09/2006

Completion date

01/09/2007

Eligibility

Key inclusion criteria

1. Age 18 to 70

2. Meeting American College of Rheumatology (ACR) criteria for Rheumatoid Arthritis (RA)

3. RA Global Functional Class I,II or III

4. Taking MethoTreXate (MTX) for a minimum of six months before screening, dose stable three months

5. No more than 10 mg/day prednisone/equivalent

6. Stable use of (if on) Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), for at least two weeks

- 7. Willing/able to comply to the protocol
- 8. Female of childbearing potential must not be pregnant, or breastfeeding

9. Females of childbearing potential and all males must use two accepted forms of contraception for the duration of the study

10. Have at least six tender and six swollen joints plus two of the following:

- a. morning stiffness more than 45 minutes
- b. Erythrocyte Sedimentation Rate (ESR) more than 28 mm/hr
- c. C-Reactive Protein (CRP) more than 1.5 mg/dl

Participant type(s)

Patient

Age group

Not Specified

Sex Not Specified

Target number of participants 186

Total final enrolment

Key exclusion criteria

1. Use of any other Disease Modifying Anti-Rheumatic Drugs (DMARDs) than MTX concomitantly or within one month prior to enrolment (in case of leflunomide, three months prior to enrolment or washout with cholestyramine)

2. Currently being treated with Tumour Necrotising Factor (TNF)-antagonists or other biologicals (washout period eight weeks)

3. Tuberculosis (TB) infection

4. Have received investigational drug one month prior to day one

5. Have received intra-articular or systemic injection with corticosteroids within one month prior to screening

6 to 26. Summary: have any other condition or increased risk of a condition or concomitant use of medication incompatible with the study (including infections, liver and kidney diseases, cardiac conditions/arrythmia, etc.) or have a history of cancer, except for distant history of cured carcinoma in situ of the cervix or Basal Cell Carcinoma (BCC).

Date of first enrolment

01/09/2006

Date of final enrolment

01/09/2007

Locations

Countries of recruitment Netherlands

Study participating centre Academic Medical Center (AMC) Amsterdam Netherlands 1100 DD

Sponsor information

Organisation Academic Medical Center (AMC) (The Netherlands)

Sponsor details P.O. Box 22660 Amsterdam Netherlands 1100 DD

Sponsor type

Hospital/treatment centre

Website http://www.amc.uva.nl/#http://www.amc.uva.nl/

ROR https://ror.org/03t4gr691

Funder(s)

Funder type Industry

Funder Name Millennium Pharmaceuticals Inc (USA)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<u>Results article</u>	results	01/12/2009	15/01/2021	Yes	No